NasdaqGS:BIIBBiotechs
Biogen (BIIB): Reassessing Valuation After Recent Share Price Recovery
If you have been tracking Biogen (BIIB) lately, the company’s shares have quietly gained 6% in the past month, recapturing some ground after a tough stretch. While there has not been a headline-grabbing event, this recent uptick could raise questions for investors: Are we seeing the start of a recovery, or is it just a temporary shift following a period of lackluster returns?
Taking a step back, Biogen’s performance over the past year has lagged with a 32% decline, and the past three years...